#USA #Draper, Utah #Nexus Spine #Tranquil #Interbody Implants

Nexus Spine's Tranquil® Interbody Implants Deliver Unmatched Performance in a Pilot Study

Nexus Spine, a pioneer in spinal technology, recently took a significant step forward by releasing promising findings from a pilot study focusing on their proprietary Tranquil® interbody implants. Conducted by Dr. Peter Campbell from Shreveport, LA, this research centers around patients at high risk for subsidence, instability, and delayed bone growth, with a special focus on those aged over 66 with suboptimal bone quality.

Throughout the study, patients undergoing anterior cervical discectomy and fusion (ACDF) were administered Nexus Spine’s Tranquil® interbody cages at multiple spinal levels. In contrast, some patients received other available interbody devices for comparative assessment. Evaluations were performed at various intervals, including two weeks, six weeks, six months, and twelve months post-surgery.

The results were nothing short of remarkable. Radiographic assessments revealed that the levels treated with the Tranquil® interbody devices exhibited zero measurable subsidence. Conversely, over 66% of the patients using competing devices showed signs of subsidence as early as two weeks post-operation. This phenomenon is critical as subsidence is a well-known indicator of spinal instability and consequent pain.

Such findings place Nexus Spine at a monumental advantage within the industry. Past peer-reviewed studies noted that comparable devices show a staggering subsidence rate of up to 52% in patients. Against this backdrop, not witnessing any subsidence at all with Tranquil® constructs represents a breakthrough in spinal health solutions.

Dr. Campbell maintains that the evidence is compelling, stating, “My radiographic outcomes showed clearly that Tranquil was the one device that ameliorated subsidence. Compared to other currently available devices on the market, Tranquil doesn’t subside.” This finding may enhance treatment standards, particularly for high-risk patients, as David Hawkes, President of Nexus Spine, elaborated, “If we can solve the key challenges for the highest-risk patients, then we can improve the universal standard of care.”

Hawkes reiterates the importance of matching the stiffness of interbody devices to that of the host bone, which is crucial for successfully preventing subsidence and ensuring stability. The pilot study thus not only highlights the effectiveness of Tranquil® devices in avoiding subsidence but also opens the door to exploring the speed of stabilization these implants offer.

Beyond just this single product, Nexus Spine’s robust patent portfolio, including U.S. Patent No. 12,279,967 for a “Porous Interbody Spacer”, underscores their commitment to innovation in spinal technology, aiming to address major challenges faced in the surgical landscape.

To elaborate further on their mission, Nexus Spine’s dedicated team is exploring how their devices can facilitate quicker stabilization, an essential aspect of spinal surgery recovery. This study has indeed cast a spotlight on their Tranquil® interbody implants, confirming that the future of spinal health may very well lie in pioneering technologies like these.

For those interested in more information about the advancements in spinal surgery technology, Nexus Spine provides comprehensive resources and insights on their website. By redefining the standards and pushing the envelope of spinal care, Nexus Spine is positively transforming the lives of patients dealing with complex spinal issues.